Where is ibs-smart located?

ibs-smart is headquartered in United States.

Is ibs-smart a funded company?

ibs-smart is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does ibs-smart rank among its competitors?

ibs-smart ranks 11th amongst 13 active competitors, of which 3 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Chosen Diagnostics, which secured $1M in Sep, 2025.

Who are the top competitors of ibs-smart?

ibs-smart's top competitors include Gemelli Biotech, AgPlus Diagnostics and Chosen Diagnostics. Among them, Chosen Diagnostics secured the most recent funding round in September, 2025.

ibs-smart - 2026 Company Profile & Competitors

ibs-smart is an unfunded company based in United States, founded in 2018. It operates as a Developer of blood test detecting IBS biomarkers. ibs-smart has not raised any funding yet. The company has 13 active competitors, including 3 funded and 1 that has exited. Its top competitors include companies like Gemelli Biotech, AgPlus Diagnostics and Chosen Diagnostics.

Company Details

ibs-smar offers a blood test that detects IBS biomarkers. The blood test is used to detect anti-CdtB and anti-vinculin biomarkers specifically associated with IBS. The test results are positive if either of the antibody levels are elevated.

Website: www.ibssmart.com/
Social
Email ID: *****@ibssmart.com

Key Metrics

Founded Year

2018

Location

United States

Stage

Unfunded

Ranked

11^th among 13 active competitors

Similar Companies

Gemelli Biotech & 11 more

View ibs-smart's full profile

ibs-smart has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ibs-smart include Gemelli Biotech, AgPlus Diagnostics and Chosen Diagnostics. Here is the list of Top 10 competitors of ibs-smart, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Gemelli Biotech 2018, Los Angeles (United States), Series A	Precision diagnostics for gastrointestinal diseases, leveraging microbiome discoveries for optimal treatment	$23M	Blue Ox Healthcare Partners, Cedars Sinai ... & 4 others	46/100
2nd	AgPlus Diagnostics 2011, Sharnbrook (United Kingdom), Seed	Handheld technology platform for disease diagnosis	-	Corporation One, Future Planet Capital & 31 others	30/100
3rd	Chosen Diagnostics 2011, New Orleans (United States), Funding Raised	Developing a novel MDx kit to diagnose a severe bowel disorder in premature infants	-	National Science Foundation, HHS & 2 others	30/100
4th	Oxford MEStar 2013, Oxford (United Kingdom), Seed	Developer of novel scaffolds for tissue engineering and stem cell delivery	$930K	Oxford University Innovation	27/100
5th	New Life Medicine Technology 2017, Hong Kong (China), Unfunded	Developer of diagnostic test kits for urine & prostate cancer screening	-	-	26/100
6th	ReverTech 2020, Loos (France), Unfunded	Developer of medical devices for bowel diseases treatment	-	-	25/100
7th	Venaxis 2012, Castle Rock (United States), Public	Developer of in vitro diagnostic tests for appendisitis	$1.95M	-	24/100
8th	EUPHORIA Munich (Germany), Unfunded	Developer of device for monitoring inflammatory bowel diseases	-	-	24/100
9th	Otakaro Pathways 2011, Christchurch (New Zealand), Unfunded	Provider of in-vitro diagnostic test for crohn's disease	-	-	24/100
10th	Tracells 2023, Yokneam Illit (Israel), Unfunded	Provider of non-invasive stool tests for IBD diagnosis	-	-	24/100
11th	ibs-smart 2018, United States, Unfunded	Developer of blood test detecting IBS biomarkers	-	-	23/100